Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Study Location:

Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)

A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)

Not Recruiting

Open to: ALL

Age: 18.0 - N/A

Medical Conditions

Non-Small Cell Lung Cancer


This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


This study will evaluate the efficacy and safety of multiple therapies in participants with locally advanced, unresectable, Stage III NSCLC with eligible biomarker status as determined by Version 8 of the American Joint Committee on Cancer/Union for International Cancer Control NSCLC staging system.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Nov 2022 Aug 2032

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Participants will receive oral alectinib twice daily with food.

Intervention Arm Group : Cohort A1: ALK-Positive (alectinib arm);

Intervention Type : DRUG
Intervention Description : Participants will receive oral entrectinib once daily, with or without food.

Intervention Arm Group : Cohort A2: ROS 1-positive (entrectinib arm);

Intervention Type : DRUG
Intervention Description : Participants will receive IV durvalumab every 4 weeks.

Intervention Arm Group : Cohort A1: ALK-positive (durvalumab arm);Cohort A2: ROS 1-positive (durvalumab arm);



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Christie Hospital Nhs Trust
    Manchester
    M2O 4BX


The study is sponsored by Hoffmann-La Roche




We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?

Read full details for Trial ID: NCT05170204
Last updated 03 February 2026

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.